Skip to main content
Premium Trial:

Request an Annual Quote

Inpharmatica Picks up ADME-related IP, Lab Space, Research Staff from ArQule

NEW YORK, June 23 - Inpharmatica said today that it plans to acquire certain assets relating to ADME (absorption, distribution, metabolism, and excretion) research from ArQule.


Specifically, Inpharmatica will take over ArQule's 10,000-square-foot Cambridge, UK, laboratories and will license some of the company's intellectual property. Fifteen of ArQule's Cambridge-based research staff will join Inpharmatica following the deal, which is subject to certain third party consents and agreements.


Financial terms of the acquisition were not disclosed.


Inpharmatica said it plans to use the newly acquired technology to enhance its PharmaCarta chemogenomics technology platform and to advance its internal discovery programs to the pre-clinical phase.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.